Vir Biotechnology Inc (VIR)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 1,150,380 1,240,730 1,433,670 1,547,360 1,590,240 1,675,080 1,810,210 1,970,760 2,077,960 2,149,860 1,952,010 2,001,010 1,431,850 876,274 737,325 650,951 716,852 812,355 563,779 380,333
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1,150,380K
= 0.00

The debt-to-equity ratio for Vir Biotechnology Inc has consistently been 0.00 across all reported periods from March 31, 2020, to December 31, 2024. This indicates that the company has not utilized any debt in its capital structure and has been primarily funded by equity. A debt-to-equity ratio of 0.00 typically suggests that the company is not relying on borrowed funds to finance its operations and growth, which may imply a lower level of financial risk. Vir Biotechnology Inc's stable and low debt-to-equity ratio may indicate a conservative approach to capital structure management and financial stability.